MAXCYTE, INC. STEPHENS ANNUAL INVESTMENT CONFERENCE | NASH2026 - MAXCYTE INC
Well, good morning and welcome to day two of the Stevens Conference. I'm Hannah Rayford. I'm on the Life Science Tools and Pharma Services team here at Stevens, and today I'm pleased to be joined by MaxSight's team. We have CEO Mahir Masood and CFO Parmeet Ahuja. Welcome. I guess I'll turn it over to you, Mahir, if you have any opening comments, and then we can launch into Q&A. Absolutely. Hannah, thank you for having us back. We were here last year, so great, great conference. I appreciate being here. I just want to open a few remarks as well. I recall last year at the same time we talked about going into that 26-time period. There were headwinds that we were dealing with back in 25 from some of our customer programs that were just rationalizing. The whole South Africa space felt like it was rationalizing 26. We had a goal coming in 26, which was get back to growth in the second half of the year, continue to maximize the efficiencies of the organization and really expand our product offerings and I think we're hitting all three going into into this this year going to next year we announced our earnings last Q3 earnings last week where we up the guide again to thirty four and a half million of total revenue obviously there's big news we acquired Akron a leading site on growth factor a reagent company that's been the space for 20 plus years that we're extremely excited about you know we're bringing a leadership team there as well on the acquisition that we can get into you know but but truly just we're hitting all the metrics that we want to get back to both the second half of the year we knew first have a tough comp expand our product offerings which we've done now and just really position us for the growth of cell therapy and that twenty seven eight nine and really outer years as well from a very healthy cost basis and I think we're hearing on all those metrics so thanks for having us yeah yeah all right well to kick things off I think the biggest news recently is Obviously, the Akron acquisition, there have been lots of changes recently. That nearly doubles annual revenue. It expands the customer base and the business pretty meaningfully into other areas. Can you just talk broadly about the strategic focus for MaxSight from here and any changes in how MaxSights is going to operate going forward? Sure. Absolutely. Great question. Obviously, MaxSIGHT has been an electric operation company focused on the non-biocell type of space since its inception. and we're continuing to build on that what akron does for us really expands us into the entire cell therapy workflow not just non-bar but also viral in addition as you mentioned you know where it doubles our revenue and you know nearly doubles our it also brings to us a few things that we haven't had in the past one is it's complementary in the non-viral space so their cytokines and growth factors are sold before they're used before and after the engineering step on our system that's something we can really commercialize and use our commercial team that we've built over the last few years to truly boost the revenues of the akron company but it also gets us into the viral space as well so overnight our drestle market truly increases we go from supporting half of the cell therapy space roughly to the entire cell therapy so 770 plus programs so to speak it also just positions us where we've talked about the goal i had was cell therapy what we said is the future of medicine that has not changed and we're seeing that still you're seeing commercial therapies come to light akron brings that to us as well where we now are embedded in the entire cell therapy space overnight we're embedded now in five once we close the deal in five commercial therapies all right we have one we're supporting right now we anticipate at least another one next year from us but they have four that they're supporting currently and they have another four in phase three that potentially can be improved in the near term as well um extremely durable revenue there brings to us you know their commercial revenue is about 40 to 45 percent of their of their current revenue these are locked in inspecting agreements so really it just it positions us to become a true self-help provider uh above and beyond just like operation while we continue to build upon the non-viral exploration platform as well yeah um for those that are less familiar with maxite and then obviously you have this new acquisition can you just explain the key product offerings in electroporation but then also the products that that Akron and Secure add to that? Sure, absolutely. The key product offerings for max size electroporation is we are, we have a seamless, all the way can take you from research to CGMP clinical and commercial product offerings. We're on our electroporation platform. We can take cell therapies and cell therapy providers from early discovery, from our research systems, all the to CGNP and commercial in a seamless optimized process. So not many companies can do that. In fact, we launched earlier this year, a system called the DTX. Our CGMP system is called the GTX. The DTx is actually even earlier in research, it's discovery, where we can work with the same protocols with therapeutic developers on their science and ensure that the protocols that we optimize early in research and discovery, they can take seamlessly into the clinic. And we've done that. We're getting good traction within DT-X. And our other systems as well. We have the ATX that gets you closer to the clinic as well, you know, we are really a true unique company in the sense of we have 13 clinical programs right now using our GTX in the clinic. Obviously one approved program, which is CashChevy, they use our system to engineer the cells. And those 13 programs are amongst 12 companies. So these are the elite programs they're using our system for. And we do it under a model that's different than most companies, which we have the SPL model. That allows us to have economics on the commercial success of any therapy. You know, at least a 1% royalty on commercial products. We receive milestones through clinical development of these products. We also receive annual lease fees from the systems being used in engineering these cells as well, in addition to the recurring consumable revenue as well. Obviously, for Akron, what it brings is above and beyond that. They have a truly unique differentiator product. Their cytokines come in a liquid. Their cytosine growth factors come in liquid format that can be stable 12 months plus at refrigerated temperatures. No one else has that. It's unique to them. They developed. Then they have a closed system solution that they've patented. They have those liquid cytokines can come in a liquid format in closed system bags that can be bio-welded into a manufacturing process. Again, sitting at stable 12-months plus stability at refrigerant temperatures. No one else has that either. Those cytokine growth factors are used before and after electroporation. It's also used before or after any viral engineering if you're not using electroperation. That's really what's been embedded in these four commercial programs, and they're specced into 95 clinical programs as well. Again, using the Cycon's growth factors and the human plasma products as well. So truly a unique offering that no one else has, very similar to us, just like our system using the clinic. Developers reference a master file that's called the DMF, drug master file. For their Cycon growth factors, they also reference Akron's drug master files. So it becomes a bed in the product. It's specced into the regulatory process, specced onto the cell therapy manufacturing process, where the FDA or EMA or equivalent regulatory bodies reference their cytokines for both factors in there as well. And obviously secure brings the ability for us to do off-target assessment of cells being engineered for safety and regulatory purposes. So we have a true offering now, a breadth of offering, to help developers engineer cell therapies. This kind of expands you from an electroporation company to more of a broad cell therapy solutions company. what made this the right time to add akron and what makes that a good fit for you all absolutely the the the right thing really is when you find an organization like akron i've known them for quite some time so the head of operations there ezekiel zillerberg has been with them helped them grow over the years as a 20 plus year old company or um you know he's he will take over as head of operate head of global akron once the acquisition closes uh they have an industry veteran there as well dave smith who's been this is from alonzo cambric's guy he's grown up growing up in the cell therapy space knows it very well has really helped grow that company since he joined them years ago um he will remain on as president chief commercial officer as well but really it's it's that breadth of offering hannah is that what it brings to us so it's a unique organization the acquisition itself was a highly competitive process it was not just us you know bidding we actually were not even the highest bidders but there's a reason why these two companies come together makes the most sense right it's it's in essence a a cell therapy uh you know a tools company now that can truly become embedded in the commercial products in two different avenues through the engineering steps through the activation and expansion steps through the field finish steps as well it just made perfect sense it's very complimentary to us in addition to that they've run a very lean organization very smartly the majority of their focus has been in the us really on viral cell therapies because that's where the space was early we have a global commercial team so we can expand their presence in in europe expand their presence in asia pacific where a lot of therapies are also being developed as well so it's really it makes us deeper into the cell therapy non-viral space by now providing those offerings before and after our engineer step and it expands our offering where now we're part of the entire cell therapy space in the final market as well it's just a win-win it's complimentary business like i could not be more excited this is why now and when you find these kind of opportunities where two companies can truly help the industry grow and come together as one it just makes perfect sense yeah um akron's gmp cytokines and growth factors compete with uh some pretty large players like sartorius thermo fisher biotechny uh can you just expand a little bit on how akron is able to compete with them and differentiate absolutely very similar to max like we compete some of those names as well what they do is highly differentiated products so as as i mentioned earlier they have they have liquid cytokines that are sitting in closed system solution bags that can bio weld into the manufacturing process these liquid cytocines unlike those that you mentioned they come at refrigerant temperatures so they're highly stable 12 months plus no one has that ability so their closed system is patented the process itself the formulation itself is proprietary to Akron so really if you think about it from a manufacturing perspective you now you hear the words about automating manufacturing right reducing cost of manufacturing well you do that by having products that are automatable products that can go into the manufacturing process only Akron has them only Aklon has it some of those competitors obviously have their own cyclones growth factors oftentimes if anybody doesn't have a liquid format it comes in a freezer so it has to be frozen it's not as stable and the closed system liquid bag solution sitting in those bags that can buy a weld that's truly unique to akron so it's a unique offering that we believe with our commercial team we can begin to really truly help them expand even outside the us and you talked a little bit about some of the cross-selling opportunities can you just talk about any revenue synergies that you kind of see with this absolutely i'll let parmi speak to that as well we've built in very little initial revenue synergies but pardon me if you want to speak to that and that can elaborate as well yeah i mean as as meyer mentioned we benefit on the max side side with a pretty established commercial infrastructure in both europe and asia where akron has not had a big presence you know most of their revenues are from the us so we certainly see hannah revenue synergies shaping up over the years first year is going to be very light touch really exchanging leads between the two teams and such so we're not building really hardly any synergies here in 2027 we'll start to see some in in 2028 and then more of an uptick in 2029 the the customer life cycle is also such where you will approach the customers at a pre-clinical stage and then as their program progresses the real growth in revenue shows up when the product goes commercial so certainly expect to see that in the two to three year timeframe, nice revenue synergies. Awesome. And then as it relates to cost synergies, I think you've cited three to four million of cost synergies and you're targeting low 70s gross margin for the combined company. Is there room for any more costs to be taken out after this? Is this kind of the initial look or what do you all see there? Yeah, very good question. So three to four million typical corporate consolidation operational efficiencies that come from a typical integration our focus will be on that and achieving that in in in 27 obviously um akron comes with a very uh good healthy uh mid 60s gross margins complemented now with max sites high 70s the combined company will be in the low 70s very attractive gross margin profile As the integration progresses, Hannah, you're spot on. We'll continue to look for opportunities, but more of that to come in the 28 timeframe. Our focus in 27 will remain sort of committed to the number we've put out. Along with those efficiencies, we expect max site cash burn to drop from exiting this year, 17 million, to less than 10 million next year. uh and then last one on akron before i move on to the broader company um it seems like these revenues are pretty sticky you talked about it being spec'd in to four commercially approved therapies at what stage of the clinical process are these typically spec'd-in uh given max side strong early stage relationships on the electroporation side do you see much of an opportunity to be able to convert some of these customers over to akron absolutely hannah so to speak when they get spectin and spectin meaning that's when they become part of that clinical manufacturing process the reagents begin you know are now referenced as part of the dmf and the regulatory filings that's at that really early clinical stage or pre-clinical stage right before a company's about to file their ind or ind equivalent outside the us and that's where we have the opportunity so if you look at what we've built here as our organization at max site site We have a global sales and FAS team, so our field application scientists sit next to our BDMs, our sales reps, and this opportunity for us to really go in there and begin to optimize the cytokines from the growth factors, these best-in-class growth factors and cytokites from Akron, optimize into the process, spec them into that process, and that's a huge opportunity for this, enormous opportunity. I mean, we're already touching a vast majority of the customers and the therapies out there. We now have the ability to truly boost them from that perspective and spec them in before they get into the clinic. And once you're in the clinic, it becomes very tough to be specced out because you're part of the manufacturing process. Your DMF is referenced as part of regulatory filing. And you can imagine on the non-viral side where they'd be speccing in our product, the ultra-precious side. They're referencing our master file. They're referring Akron's master file, which now becomes a much bigger portion of the regulatory filing as well. So a true opportunity to really get in there early in the preclinical process, early in the clinical process, and begin to start to really get the traction that I think we can provide to Akron. Yeah, that's great. All right. Finally, moving past Akron, there's been a number of macro headwinds in the life science tool space that's impacted your core electroporation business. but it seems like we've finally started to kind of hit an inflection point over the last couple quarters. Can you just talk about what you're seeing in terms of demand across instruments, consumables, and licenses, and how do you see these kind of playing out into 2027? You want me to talk about the market headwinds and then from there, and then you talk aboutthe consumables and everything else. So from a macro environment, Hannah, we're seeing there's continuous stability. So if you look at where we were in 24, well, let's take a step back. In 21 is where VC-funded cell therapy programs were at their peak. Those days are not coming back, but we don't want them to come back. That really was kind of a bubble for the cell therapy market. 24 funding was about $3 billion overall across 126 programs roughly. 25 funding was more than that, about 19% more, about 3.5. 26 is looking to be a little bit more than 25 on par with that. what we're seeing though is programs are funded as they are more late stage so the late stage programs are what's getting funded the early stage ones obviously unless you can show efficacy we can show a true proof point it's a bit tougher to get funded an example we bring up is you know a great company one of our partners is Alaterra you know what they have a phase three program and they receive funding I believe over 150 million just a few months ago so those are kind of programs being funded late stage and that's what you want to see it It builds very nicely in our model, but with our model and Akron's model, I'll get back to it again, which is the more you are specced in and embedded in these late-stage clinical programs, the more of a chance you have to be embedded in commercial programs. That's where your revenue growth starts to happen. Parmeet, did you want to elaborate on where we see the consumables? Yeah, absolutely. I mean, Q3, certainly core revenue was up 27%. And, Hannah, as you saw, growth was across the portfolio, SPL and non-SPL. Customer's PA revenue grew 20%. If you look at peer revenue trailing 12 months, we're at mid-single digits, very healthy instruments at a very strong quarter, great funnel conversion by a sales team, with and without contributions from the Genentech partnership. So, you know, as we look ahead, you know, we're going to be growing next year from the stable base. You know, I expect PA revenue to be right in that range of mid-single digit growth to continue. Licenses tend to be very stable, kind of in that same growth rate. Instruments, as our team continues to convert very, very strongly, I think we'll kind of follow that same path of mid to high single. And you're seeing the benefit of operating leverage show up in our P&L. You know, we've kept a very nice tight lid on operating expenses. Net losses were down almost 50% year-to-date, year-on-year. So you'll continue to see the benefit of that operating leverage as we move forward. There seems like there's still a bit of a split between funding for later-stage assets and earlier-stage selling gene therapy assets. I think you kind of called out some of that, but can you just talk about what you're seeing in your customer base specifically? Are there still pockets of weakness that you would call out that you might see coming back in the next year or so? Yeah, pockets of weaknesses. I mean, obviously, earlier-stage or earlier- stage programs, they're still having a hard time being funded. um i would say not so much to focus on earlier stage or you know our pockets of weakness what we are seeing actually is earlier stage programs in academia clinical trials are expanding we are seeing that so you're actually seeing academic clinical trials really take effect and we began to actually target those trials and in that 20 late 24 25 period realizing that i can kind of see the market as well for future industry trials as well so that's where we're seeing pockets that previously maybe were not as strong that we're starting to see really inroads there um you know from that perspective uh if if you're talking about you know what we're seeing in terms of maybe broader than that or some of the indications so to speak obviously autologous is still dominating the autologues for allogeneic market um it's about 60 autologus versus allogeneics cell therapy is still being dominated by xvo programs so the number of xvo problems in the clinic are about 40% of all ex-vivo programs. The number of end-vival programs in the clinic, about less than 10%. 10% or less. That's where you're still seeing the strength of cell therapy there. T-cells are still a predominant. Cells are being engineered. Oftentimes, your CAR-Ts is a majority of that. You see TCRs as well. You're seeing growth in HSCs, growth in TILs as well, growth and NK cells. Across the board, you're seeing that. Um, a few things that have changed as well as the space itself seems to be going after more solid tumors in the oncology space. I think about, uh, solid tumors now accounts for 40 to 45% of these indications being pursued. It used to be far less than that. It was more heme or, you know, blood cancers that were being pursued, um, so it's, it's I don't know if there's really pockets. It's just more, that's just what the landscape is that we're, we're playing in right now, Hannah. Okay. That's helpful. And then turning to the SPL program revenue side, you recognized an unexpected milestone in 3Q, and you've seen some pretty strong performance from Kastjevi Royalties. Can you just talk about what you see going forward on the royalty and milestone front? Yeah, certainly a very strong quarter on the non-core side of things, $2 million. as you pointed out, Hannah, a million coming from royalties, one million from a milestone payment. So Casgivy continues to ramp up very well. You know, their Q3 sales were 99 million, up 30%, I believe, sequentially. 750 patients initiated already. So as that program scales, we'll be benefactors of that. very excited to see that that progress with our customer with our partners program um one change we will be making on the royalty side of things hannah we're going to be moving the royalties reporting as part of core given that it's becoming a meaningful part of the business we want to give investors more visibility into the recurring side along with our pas licenses royalties will we believe form a big part of that recurring stream and meaningful stream going forward milestones will continue to be reported separately as you know they tend to be a bit unpredictable sort of one time looking forward we expect milestones again you know very much dependent on partner development milestones we expect in 2027 in the very low seven figures also because the milestone we received in q3 was actually expected in 20 27 so there's that pull forward as typically can happen with milestones and then kind of looking a little bit further out with all of the different pieces of your business kind How do you see the business growing across electroporation? You've got preclinical and then SPL customers, multi-platform licenses, Secure and Akron. Can you just parse out kind of how you see each of these pillars growing over the next few years? Yeah. I mean, I think starting off certainly 27, I've commented on that, trailing 12-month revenues for PAs, certainly reaching that many single digits licenses tend to be at the same pace we expect instruments to be a bit higher than that um you know cast chevy royalties continue to ramp up i think as we look further beyond my hair you know we've got opportunities with a couple of programs that are in in in phase three trials late stage getting approved here in the 12 to 18 month time frame that's when that certainly will ramp up about volumes revenues in multiple different ways that's exactly if I can if I get to that as well so we expect at least hopefully knock on wood one more program being approved next year that that's that's a meaningful program for us as well potential for you can have another one possibly but potential for two more also approved in that early 2028 as well. So you look at it and this is just on the max I side you look Akron there's a potential approval for them next year for those for registrational trials same thing again in 28 potentially a few more approvals for them as well so you can look at a time period really in that late 27 early 28 where the combined company we're one company at that point uh you know we're we're now part of potentially eight to nine commercial programs right that's that's a very different profile than we had in the past um we also have the multi-platform license model that we have now that's become complementary to the spl model which the spl models always going to be a mainstay in how we work with biotech companies but for with large pharma, I believe that model that we have with Genentech can be replicated with other large pharmas as well. So truly, we have different ways now of really creating that recurring sticky revenue and expanding outside of just non-viral, outside of juste non-viral with baby biotechs or mid-sized biotech. It's an expansion across the entire self-help workflow. Viral, non-viro, biotecs, large phharma, highly concentrated commercial revenue. That's what we're looking forward to. And then speaking of the multi-platform licenses that you just mentioned, how is the Genentech relationship contributing to revenue, and is this helping drive the kind of recent stabilization we've seen over the last few quarters? Do you want to take that from me? Yeah, absolutely. We're excited about this model, the pharma model, as we call it. Very exciting contribution, certainly, here in Q3. We are Genentech's enterprise partner across their cell therapy portfolio. You know, they have two programs in the clinic, many more preclinical, some in research. So very, truly very excited about the opportunity. Q3 saw a bolus of instruments. PA's consumables behind those instruments are yet to follow. We'll see some in Q4, but certainly more in 27. We certainly expect more instruments as well. Truly excited about this opportunity, this model that complements very nicely the small to medium biotech model, what we call the SPL model. That's right. That's great. And then on that pipeline for additional multi-platform licenses, should we expect more of these in the near term? And is there anything different about kind of the timing that it takes to bring these on? Since they're larger, more complex organizations, does that take longer? Is it a bit faster since they tend to be better funded? Yeah, no, great question. So the sales cycle is longer. Obviously, large pharma, for example, working with Genentech, this was a 24-month process. We had a bake-off, obviously, between our systems and competing systems. That took 18 months as well. But the whole negotiation was at least a 24‑month process, so the process takes a little bit longer. Also, it's a little different. On the SPL model, you're being spec'd in on a program-by-program basis. With the large pharma model, it's across all the platforms. So whatever they're in the clinic for, whatever pre-clinical programs they have that they plan to take into the clinic, so it truly becomes a platform model across all of their programs. That takes some time to negotiate as well. The other aspect of it is, and we realize this, there are obviously less large pharmas pursuing cell therapy than the biotechs. So you don't have as many companies that you're pursuing. But I feel, you know, I've always had a goal that once we have, we work with a big biotech, which we're working with now, we can replicate that and hopefully we can sign one of these every single year, maybe two, you never know, but one a year at least. But it takes some time. We're talking right now with a few also large pharmas. We'll see how we can, you Know, grow with them as well. But again, it's a longer sales cycle, but it's bigger potential future with these large pharas as well because you're embedded across their clinical platforms and preclinical platforms. And then turning to Secure, I know this is a small piece of the business, but can you just talk about how this has trended versus your expectations, and could Akron customer relationships further accelerate their sales? Sure, sure. I mean, obviously, you know, it's taken a little bit slower than we anticipated with Secure. We have a recurring licensing revenue from Secure The services side has been a little bit lumpy for us, quarter to quarter. I think there's still adoption of secures assays. And just the industry itself adopting these assays being done by, you know, another company. Oftentimes companies try to do these assails themselves. We believe they should be done by a secure company doing it. But there is opportunity there. I mean, obviously with Acron, we now have exposure to the entire self-healthy market, borrow and non-borrow. So, you know, so obviously that gives us another inroad to be able to go in there and really help with the safety optimization of these therapies. But the traction has been slow, Hannah. Slow, but it's been steady at the same time. Great. And then post-Akron, I think you've mentioned that M&A is kind of off the table for now. Any additional M&As? are there any other areas in the business that need investment or is the priority just kind of executing from here and integrating that business sure let me take that and then probably if you want to add in as well obviously you know right now it's about executing on the max site business it's about executing the Akron business and the integration and as we talked about the integration be a light integration right they have a they have a very solid team they're great leadership great even head of operations great head of quality it's by integrating them early executing there you know and continue to execute we've I think now we have we've been consensus now three straight quarters we look to keep doing that every every quarter both us and with acquisition background doing it now from a combined company at the same time there are some investments that we make we make them very efficiently the same way we launched the DTX earlier this year from an efficient cost basis there'll be opportunities there where we can continue to look to see how we can expand our offerings both on the max I signed the Akron side from a very efficient perspective as well how we can increase our offerings um you know we're always you know, we're looking to expand and become a broader cell therapy tools provider which we're not doing but really the focus over the next 12 months is just continue execute integrate a great company into into an already great company and that's where the focus will be headed. Great and then finally uh Akron is already adjusted a bit of positive uh they should accelerate your path to adjust it even a break even as a company I think you talked about cash burn being less than 10 million next year how do you view the timeline to cash flow positive sure take this one for me but then I want to add it then sure sure so and now you've got that very well you know we started the year with a guide of about 20 million of cash burn we've done better we've kept a a real good lid on operating expenses. When we exit this year with, I call it legacy max site, with 17 million burn. Next year with the contribution of Akron, their EBITDA, their cashflow positive, we expect seven to eight million. That will bring our cash burn, combined company cash burn along with our efficiencies of three to four million below 10 million, right? We also expect to exit after the transaction is concluded with 40 to 45 million in cash, a very nice runway um uh for our cash burn which by the way will we expect will continue to continue to come down as operating leverage takes hold you know top line growing we don't see a need to increase operating expenses from here you can pencil in inflation growth and that's about it and then from there operating leverage does does does its thing and we expect as we move into 2028 um really exiting 2027 we should be in spitting distance in terms of cash flow positivity yeah and if i can add to that i think i'd like to say our track record i think shows we can execute on that i mean if we take a step back hannah just a few years ago we used to burn i think it was 50 million or 50 million plus of annual burn on our own now we brought that down to under you know under 20 million in a tough environment in a truly tough environment as parmi mentioned with the akron acquisition there's clearly synergies that we have that we continue to grow on that and and we have a goal our goal is to continue the growth on the top line like we did this year uh both on us on the akron side and continue to get to cash flow positivity that that's our goal and i think you said it for me we're within spinning distance and we can execute towards that so we feel and this is we see we see a few years out where we can have a true company that is expect into multiple commercial programs highly sticky highly durable um continue to grow and that's where the space is when you hear cell therapy space has a 20 growth that comes from being inspecting commercial programs that's for the majority of that growth is coming from and that's what we're building and and in essence the as part of me mentioned we can leverage the scale we have now both on our side and on akron's side without having to increase our operating expenses so we we can double triple revenues without having truly grow too much as an organization other than natural inflationary growth and i'm confident we can do and we have the right team so we've taken the last few years for me joined us from from you know from agilent um and has done a tremendous job i think helping me and helping the organization really get to that that i say maturity of operating as well we have a fabulous commercial team we've built here uh you know we have you know uh we have people born from sartorius from stem cell therapeutics from thermo and ge these are leading our north american european and our our asia pacific sales um high quality regulatory person has joined us as well uh it's it's just we have a great organization we're building here well i think we are out of time now so thank you for being here today thank you hannah thank you appreciate it we'll see you next year yes
- Company
- MAXCYTE INC
- Keywords
- MAXCYTE INC